Citations

Clear

1575 citation(s) found for "Im, Gene".

Gene Expression Profiles Indicative of Reversible Injury in Experimental Renal Artery Stenosis
Osman, Mazen, Lorenzo, Silvana De, Johnson, Ruth, Lien, Karen, Grande, Joseph P.

Mayo Clinic

The FASEB Journal | April 17, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.03168 Get It

Aim The aim of this is to identify the gene expression profiles indicative of reversible versus irreversible injury in experimental (murine) renal artery stenosis (RAS). Method Two‐kidney‐one‐cuff hypertension was established by placement of a polytetrafluoroethylene cuff on the right renal artery (N=18). Sham surgery was performed by manipulating the right renal artery without cuff placement (N=6). To determine potential reversibility, the cuff was removed at 7 days (7D cuff‐off, N=6) and 14 days (14D cuff‐off, N=6) after initial RAS surgery. In a control RAS group, the cuff was left in place for 28 days (28D RAS, N=6). Kidneys were harvested at 28 days for assessment of atrophy and fibrosis. Renal blood perfusion and oxygenation were measured using 16.4T MRI. RNASeq analysis was performed on all the groups at 28 days following initial surgery. Results Following cuff placement, intra‐renal perfusion was reduced by 65% (p<0.0001 vs. baseline). In the 7D cuff‐off group intra‐renal perfusion was restored to baseline values after cuff removal, whereas in the 14D cuff‐off group perfusion was not significantly improved following cuff removal. In the 28D RAS group the reduction in perfusion was maintained throughout the study period. The 7D cuff‐off group had a significantly lower % atrophy (7 ± 2.2%, p=0.0042) and % area of interstitial fibrosis (0.57 ± 0.08 %, p<0.0001) compared to 28D RAS group (atrophy 66 ± 13%, area of fibrosis 7.79 ± 0.89 %). The 14D cuff‐off group had severe atrophy (56 ± 16.6%) and interstitial fibrosis (5.05 ± 1.22%) similar to that seen in 28D RAS group. RNASeq analysis data were normalized to appropriate sham controls in all the groups and was performed at 28 days following initial surgery. Induction of greater than Log2 ratio >2 and p values < 0.00001 were considered significant (following adjustment for multiple comparisons). Fibrosis associated genes were differentially regulated in the 7D cuff‐off compared to the 14D cuff‐off and 28D RAS group (table ). Conclusion We conclude that cuff removal at 7 days is associated with relative preservation of renal structure, indicating that renal injury at this point is reversible. We have identified a number of fibrosis associated genes that are differentially regulated in the 7D cuff‐off group versus 14D cuff‐off group. Further analysis will determine the functional relevance of these differentially regulated genes. Support or Funding Information This project was funded by National Institutes of Health, NIAID R01 AI100911. Values of Log 2 Ratio Genes 7D Cuff‐off vs Sham 14D Cuff‐off vs Sham 28D RAS vs Sham COL1A1 0.96 2.62 2.23 COL1A2 0.79 2.07 1.91 COL3A1 1.26 2.60 2.35 MMP12 1.24 2.85 2.95 MMP14 1.34 2.70 2.55 MMP19 2.89 3.86 4.05 MMP2 1.55 3.49 3.22 MMP7 6.96 9.22 9.59 MTOR −0.46 −1.67 −2.06 SERPINE1 1.25 3.37 2.35 TGFB1i1 0.44 1.46 1.53 TGFB2 0.82 1.83 1.97 TGFB3 0.59 1.91 1.99 TGFBi 0.98 1.88 2.02 KLF15 −0.90 −1.76 −2.60 UBD 4.49 6.23 6.18 TIMP1 2.94 5.30 5.16 TIMP2 0.50 1.46 1.52 TIMP3 −0.35 −1.26 −1.36 HSPB1 0.16 2.00 2.13 HSPB8 1.51 2.26 2.30 CCL2 3.44 4.89 4.31 CCL12 2.88 3.71 4.12 SERPINE1 1.25 3.37 2.35 SERPINE2 1.17 2.39 2.35 SERPINF1 2.02 2.76 3.11 SERPINF2 −0.51 −2.03 −2.71 SERPING1 1.15 1.81 2.09 CLU 1.45 2.54 3.07 STC1 0.45 1.99 2.12 SPP1 1.75 3.06 3.37
Skeletal muscle gene transcript changes in type 1 diabetic patients following insulin deprivation
Karakelides, Helen, Asmann, Yan W. , Bigelow, Maureen L., Short, Kevin R. , Dhatariya, Ketan , Nair, K. Sreekumaran

Mayo Clinic

The FASEB Journal | April 10, 2020 | Volume: 21 | Issue: 5 | Pages: No page available

10.1096/fasebj.21.5.a343-d Get It

Insulin resistance is associated with skeletal muscle mitochondrial (mito) dysfunction in many conditions including type 2 diabetes (T2D). Poor glycemic control in T2D is associated with muscle mito gene transcript alterations. It is unknown whether muscle mito changes are related to reduced insulin action or vice versa. We obtained vastus lateralis muscle biopsies from 7 type 1 diabetic patients (T1D) following 8–12 hrs of insulin deprivation (I−) and replacement (I+) and measured skeletal muscle mito ATP production (MATP) and gene transcripts. I− and I+ changed glucose and glucagon levels (glucose=291±15mg/dl in I− vs 97±3 in I+ and glucagon=79.8±15.3 pg/mL in I− vs 47.3±5.9 in I+, p<0.04). Whole body O 2 consumption increased during I− by 15% (p<0.05) but maximal MATP decreased by 21.3–27.9% (p<0.05). Gene transcript profiling in skeletal muscle analyzed using Affymetrix GeneChip arrays showed alterations in 2355 transcripts. Pathway analysis showed down‐regulation of oxidative phosphorylation and arachidonic acid metabolism, and up‐regulation of VEGF and actin cytoskeleton signaling in I−. We conclude that the reduced insulin action that occurred during I− in T1D resulted in substantial changes in gene transcript levels of muscle mito genes and reduced maximal MATP, supporting that insulin is key regulator of muscle mito function by exerting its effect at various levels. Supported by NIHRO1DK41973.
Poly(ethylene glycol)–Poly(beta-amino ester)-Based Nanoparticles for Suicide Gene Therapy Enhance Brain Penetration and Extend Survival in a Preclinical Human Glioblastoma Orthotopic Xenograft Model
Mondal, Sujan Kumar , Tzeng, Stephany Y. , Rui, Yuan , Al‐kharboosh, Rawan , Kozielski, Kristen K., Garcia, César A. , Quiñones‐Hinojosa, Alfredo , Green, Jordan J. , Mondal, Sujan K, Al-Kharboosh, Rawan, Bhargav, Adip G. , Green, Jordan J , Tzeng, Stephany Y , Kim, Jayoung , Kozielski, Kristen

Mayo Clinic

ACS Biomaterials Science & Engineering | April 6, 2020 | Volume: 6 | Issue: 5 | Pages: 2943-2955

10.1021/acsbiomaterials.0c00116 | PMID 33463272 Get It

Hypochlorous acid-generating electrochemical scaffold eliminates Candida albicans biofilms
Zmuda, Hannah , Mohamed, Abdelrhman , Raval, Yash S. , Call, Douglas R. , Patel, Robin , Beyenal, Haluk , Zmuda, H M , Mohamed, A , Beyenal, H , Patel, Robin , Schuetz, Audrey N. , Raval, Yash S.

Mayo Clinic

Journal of Applied Microbiology | April 6, 2020 | Volume: 129 | Issue: 4 | Pages: 776-786

10.1111/jam.14656 | PMID 32249986 Get It

Abstract Aims Wound infections involving Candida albicans can be challenging to treat because of the fungus’ ability to penetrate wound tissue and form biofilms. The goal of this study was to assess the activity of a hypochlorous acid (HOCl)-generating electrochemical scaffold (e-scaffold) against C. albicans biofilms in vitro and on porcine dermal explants (ex vivo). Methods and Results C. albicans biofilms were grown either on acrylic-bottom six-well plates (in vitro) or on skin tissue excised from porcine ears (ex vivo), and the polarized e-scaffold was used to generate a continuous supply of low concentration HOCl near biofilm surfaces. C. albicans biofilms grown in vitro were reduced to undetectable amounts within 24 h of e-scaffold exposure, unlike control biofilms (5·28 ± 0·034 log10 (CFU cm-2); P &lt; 0·0001). C. albicans biofilms grown on porcine dermal explants were also reduced to undetectable amounts in 24 h, unlike control explant biofilms (4·29 ± 0·057 log10 (CFU cm-2); P &lt; 0·0001). There was a decrease in the number of viable mammalian cells (35·6 ± 6·4%) in uninfected porcine dermal explants exposed to continuous HOCl-generating e-scaffolds for 24 h compared to explants exposed to nonpolarized e-scaffolds (not generating HOCl) (P &lt; 0·05). Conclusions Our HOCl-generating e-scaffold is a potential antifungal-free strategy to treat C. albicans biofilms in chronic wounds. Significance and Impact of the Study Wound infections caused by C. albicans are difficult to treat due to presence of biofilms in wound beds. Our HOCl producing e-scaffold provides a promising novel approach to treat wound infections caused by C. albicans.
PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States
Wijarnpreecha, Karn , Scribani, Melissa , Raymond, Pascale, Harnois, Denise M. , Kim, Donghee , Wijarnpreecha, Karn , Kim, Donghee , Keaveny, Andrew P. , Ahmed, Aijaz

Mayo Clinic

Journal of Gastroenterology and Hepatology | March 27, 2020 | Volume: 35 | Issue: 10 | Pages: 1789-1794

10.1111/jgh.15045 | PMID 32220085 Get It

Abstract Background and Aim The association between palatin‐like phospholipase domain‐containing 3 ( PNPLA3 ) I148M ( rs738409 ) polymorphism and mortality is not well understood. We investigated the impact of PNPLA3 I148M ( rs738409 ) polymorphism on overall and cardiovascular mortality based on the presence of nonalcoholic fatty liver disease (NAFLD). Methods The third National Health and Nutrition Examination Survey (NHANES) from 1991 to 1994 and National Health and Nutrition Examination Survey III‐linked mortality data through 31 December 2015 were utilized in this study. Results Of 4814 participants, 50.7% were homozygous for the C‐allele and 12.6% were homozygous for the G‐allele. During a follow up of 20 years, there were a total of 1255 deaths, 422 attributed to cardiovascular disease. There was a significant association with overall mortality among those with the PNPLA3 I148M ( rs738409 ) GG genotype (hazard ratio [HR] 1.34, 95% confidence interval [CI] 1.02–1.77) or G‐allele (HR 1.22, 95% CI 1.09–1.36) in the general population. NAFLD with homozygous PNPLA3 I148M ( rs738409 ) GG genotype had higher overall mortality after adjusting for multiple metabolic risk factors (HR 1.45, 95% CI 1.01–2.08). The PNPLA3 I148M ( rs738409 ) G‐allele had a tendency of increased cardiovascular mortality in the total population. This association was not noted in those with NAFLD. Conclusions The homozygous PNPLA3 I148M ( rs738409 ) GG genotype showed an increase in overall mortality in the general population and NAFLD independent of multiple metabolic risk factors.
Abstract PD5-11: Association of immune gene expression with outcome in the MARIANNE phase 3 clinical trial in HER2-positive metastatic breast cancer (MBC)
Perez, Edith A. , Haas, Sanne Lysbet de, Barrios, Carlos H. , Eiermann, W., Im, Young‐Hyuck , Burris, Howard A. , Lambertini, Chiara , Hoersch, Silke, Patre, Monika, Ellis, Paul Anthony, Toi, Masakazu , Conte, PierFranco , Martín, Miguel , Pieńkowski, Tadeusz , Pivot, Xavier B.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: PD5-11-PD5-11

10.1158/1538-7445.sabcs19-pd5-11 Get It

Abstract Introduction: Although HER2+ breast cancer (BC) is considered a moderately immunogenic tumor, several studies have shown a role of pre-existing immunity associated with favorable long-term prognosis and better response to treatment. In this study, we performed exploratory analyses to assess whether the efficacy of HER2 targeted treatment in the MARIANNE trial correlated with immune gene expression. Methods: MARIANNE (NCT01120184) is a phase 3 study in patients (pts) with centrally confirmed HER2+ local advanced/metastatic BC naïve to prior treatments in the advanced disease. Pts were randomized (1:1:1) to trastuzumab+taxane (HT), T-DM1, or T-DM1+Petuzumab (P) and the trial showed noninferior PFS of T-DM1 and T-DM1+P vs HT. Gene expression (RNA) analysis was performed on tumor samples by a custom 800-gene codeset on the nCounter platform. PD-L1, CD8 expressions and immune gene signatures (sign) analyses were assessed by multivariate Cox regression models using median (cut-off) as categorical variable and adjusted by prior HT, presence of visceral disease, world region, baseline ECOG, measureable disease at baseline, therapy setting, HER2 mRNA expression, PIK3CA mutation status. Results: MARIANNE randomized 1095 pts (HT, n=365; T-DM1, n=367; T-DM1+P, n=363). Gene expression results were available for 671 pts (61.3% of the intent-to-treat [ITT] population) which was representative of ITT. In ITT, HR below 1 was observed when comparing pts with high (&gt;median) vs low (≤median) immune gene expression by clinical outcome suggesting a potential association of high immune marker expression with improved PFS (Table 1) and to some extent with OS (data not shown). This association was primarily observed in the T-DM1 arm where the HR suggested a risk reduction of disease progression(PD)/death especially in the high Teff, high PD-L1 and high CD8 subgroups, and to some extent in the HT arm (Table 1). When assessing the predictive impact on PFS by comparing T-DM1 vs HT, HR below 1 was observed especially in pts with high Teff signature, high PD-L1 and high CD8 expressions (HR 0.67 (95% CI (0.47-0.95)), HR 0.68 (95% CI (0.48-0.97), and HR 0.64 (95%CI 0.44-0.93), respectively). When comparing T-DM1+P vs. HT, HR below 1 was observed especially in pts with low Teff signature and low PD-L1 expression (HR 0.70 (95% CI (0.50-0.99), and HR 0.68 (95% CI (0.48-0.96) respectively). No clear differences between immune gene expression subgroups was observed when comparing treatment arms in regards to OS (data not shown). Conclusions: In the exploratory analysis from the MARIANNE study, high immune gene expression, especially in the high PD-L1, CD8 and Teff subgroups, showed an association with improved clinical benefit with HRs reflecting for a risk reduction of PD/death for PFS and partially for OS. This association was less obvious in the T-DM1+P arm. When comparing the treatments effect, the data showed a potential impact of high Teff signature, and high CD8 and PD-L1 expressions on T-DM1 and less on HT. The potential opposite association of low Teff signature and low PD-L1 expression with improved benefit in the T-DM1+P arm was unexpected and needs further investigation. Table 1: Prognostic biomarker effect on PFSBiomarker by categories (&gt;Median vs ≤Median)HR (95% CI) ITT n=671HR (95% CI) HT n=220HR (95% CI) T-DM1 n=227HR (95% CI) T-DM1+P n=224Teff sign0.89 (0.73-1.09)0.97 (0.68-1.38)0.64 (0.45-0.91)1.09 (0.75-1.58)Th1 cytokine sign0.91 (0.74-1.11)0.92 (0.64-1.31)0.78 (0.55-1.11)0.96 (0.67-1.36)Checkpoint inhibitor sign0.95 (0.78-1.15)0.91 (0.64-1.29)0.90 (0.64-1.26)1.02 (0.71-1.47)PD-L10.80 (0.66-0.98)0.79 (0.55-1.13)0.62 (0.44-0.87)1.07 (0.74-1.55)CD80.91 (0.75-1.11)1.10 (0.77-1.57)0.66 (0.46-0.93)0.98 (0.68-1.41) Citation Format: Edith A Perez, Sanne Lysbet de Haas, Carlos H Barrios, Wolfgang Eiermann, Masakazu Toi, Young-Hyuck Im, Pier Franco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier B Pivot, Howard A Burris III, Chiara Lambertini, Silke Hoersch, Monika Patre, Paul Anthony Ellis. Association of immune gene expression with outcome in the MARIANNE phase 3 clinical trial in HER2-positive metastatic breast cancer (MBC) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD5-11.
Abstract PD3-01: Population-based breast cancer risk estimates for predisposition gene mutations: Results from the CARRIERS study
Gao, Chi , Eckloff, Bruce W., Samara, Raed, Klebba, Josh, Auer, Paul L. , Gaudet, Mia M. , Haiman, Christopher A. , Vachon, Celine M. , Goldgar, David E. , Nathanson, Katherine L. , Nathanson, Katherine L , Couch, Fergus J. , Hu, Chunling , Hart, Steven N. , Gnanaolivu, Rohan , Lee, Kun Y. , Na, Jie , Boddicker, Nicholas , Ambrosone, Christine B. , Anton‐Culver, Hoda , Bernstein, Leslie , John, Esther M. , Neuhausen, Susan L. , Olson, Janet E. , Pal, Tuya , Palmer, Julie R. , Sandler, Dale P. , Taylor, Jack A. , Trentham‐Dietz, Amy , Vachon, Celine M. , Weinberg, Clarice R. , Yao, Song , Weitzel, Jeffrey N. , Domchek, Susan M. , Kraft, Peter , Polley, Eric C.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: PD3-01-PD3-01

10.1158/1538-7445.sabcs19-pd3-01 Get It

Abstract Germline mutations in several cancer predisposition genes included in hereditary multigene testing panels have been associated with increased breast cancer risk. However, estimates of breast cancer risks for each gene have in large part been derived from studies of high-risk populations enriched for family history of breast and ovarian cancer, young age of breast cancer diagnosis, or founder mutations. The breast cancer risks associated with mutations in many of these genes in the general population remain to be clearly defined. As clinical hereditary cancer genetic testing is already provided to many women at increased risk and may soon be offered to all breast cancer patients, population-based risk estimates associated with predisposition gene mutations will be needed for appropriate clinical management of mutation carriers. The “CAnceR RIsk Estimates Related to Susceptibility” (CARRIERS) consortium of 17 cohort-based case-control, population-based case-control, and family studies focused on estimation of population-based breast cancer risks and penetrance analysis for mutations in known and candidate breast cancer predisposition genes. Germline DNA from 39486 breast cancer cases and 35868 matched controls was subjected to dual bar-coded QIAseq multiplex amplification of 1733 target regions in 37 predisposition genes. Products from sets of 768 samples were pooled and sequenced in each lane of a HiSeq 4000 system. Mutations were called by GATK Haplotype Caller and Verdict. High quality sequence data was obtained for 99.3% of target regions. Here we report on results from 34741 population-based breast cancer cases and 32728 matched unaffected controls. The mean age of breast cancer diagnosis for cases was 61.2 years and mean age for controls was 61.1 years. Overall, 20.9% of cases and 14.3% of controls had a family history of breast cancer. Furthermore, 74.3% of cases and 75.8% of controls were non-Hispanic white, whereas 13.3% of cases and 15.3% of controls were African American. Among cases with tumor information available, 81.7% were ER-positive and 7.7% were triple negative breast cancers (TNBC). We assessed mutation frequencies in 24 genes including 12 established breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, andTP53). The overall mutation frequency was 6.2% in cases and 2.7% in controls. Case-control association analysis after adjusting for study, age, family history of breast cancer, and race/ethnicity showed that BRCA1(OR=7.45; 95%CI:5.24-10.95) and BRCA2(OR=5.31; 95%CI:4.15-6.88) were associated with high risks of breast cancer in the general population. However, PALB2mutations were only associated with moderate risks (OR=3.63; 95%CI:2.57-5.26). ATMmutations conferred attenuated risks (OR=1.83; 95%CI:1.47-2.28) relative to studies of high-risk families or young onset breast cancers. NBNmutations were not associated with increased breast cancer risk. Mutations in BARD1, RAD51C, RAD51Dand XRCC2were specifically significantly associated with moderate risks of ER-negative breast cancer and TNBC, whereas mutations in ATM, CDH1and CHEK2were specifically significantly associated with ER-positive disease. On the basis of these findings age-related absolute breast cancer risks for commonly mutated genes were estimated. Overall, results from the CARRIERS study establish that mutations in predisposition genes are associated with lower risks of breast cancer in the general population than in enriched populations including high-risk families and young onset, bilateral, or multiple primary cases. We anticipate that the results from this study will inform cancer screening and other risk management strategies for women in the general population with mutations in predisposition genes. Citation Format: Fergus J Couch, Chunling Hu, Steven N Hart, Rohan Gnanaolivu, Kun Y Lee, Jie Na, Chi Gao, Nicholas J Boddicker, Bruce Eckloff, Raed Samara, Josh Klebba, Christine B Ambrosone, Hoda Anton-Culver, Paul Auer, Leslie Bernstein, Mia M Gaudet, Christopher Haiman, Esther M John, Susan Neuhausen, Janet E Olson, Tuya Pal, Julie R Palmer, Dale P Sandler, Jack A Taylor, Amy Trentham-Dietz, Celine M Vachon, Clarice Weinberg, Song Yao, Jeffrey N Weitzel, David E Goldgar, Susan M Domchek, Katherine L Nathanson, Peter Kraft, Eric C Polley. Population-based breast cancer risk estimates for predisposition gene mutations: Results from the CARRIERS study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD3-01.
Abstract P5-03-07: Distribution of the 21-gene recurrence score (RS) assay (Oncotype DX) in carriers of germline mutations associated with breast cancer predisposition syndromes
Choong, Grace M. , Yadav, Siddartha, Leon‐Ferre, Roberto A. , Liu, Minetta C. , Giridhar, Karthik V. , Polley, Eric C. , Goetz, Matthew P. , Couch, Fergus J.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P5-03-07-P5-03-07

10.1158/1538-7445.sabcs19-p5-03-07 Get It

Abstract Background: BRCA1/2 carriers have higher scores in the 21-gene RS assay compared to non-carriers. Little is known about the 21-gene RS patterns in women harboring germline mutations in genes outside BRCA1/2. Methods: We utilized the Mayo Clinic Breast Cancer Study Registry to identify individuals with non-metastatic estrogen receptor positive breast cancer and clinical 21-gene RS results available. We cross-referenced this with an institutional registry of patients tested for hereditary cancer genes, either from the electronic health record or from a research study conducted using a custom QIAseq multiplex amplicon-based panel (Qiagen). The latter assay covered target regions of all coding regions for the following predisposition genes: ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, ERCC2, FANCC, FANCM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, PRSS1, STK11, TP53, and XRCC2. Student’s t-test was used to compare 21-gene RS between carriers, non-carriers, and specific carrier genes (JMP v 14.0). Results: 282 patients were identified with early stage breast cancer and 21-gene RS available, including 85 known mutation carriers and 197 non-carriers (or unknown carrier status). Germline mutations were identified in CHEK2 (n=25), BRCA2 (n=18), ATM (n=10), BRCA1 (n=5), PALB2 (n=5), TP53 (n=3), FANCM (n=2), MUTYH (n=2), PMS2 (n=2), PPM1D (n=2), RECQL (n=2), BARD1 (n=1), BLM (n=1), CDH1 (n=1), ERCC2 (n=1), FANCC (n=1), MSH6 (n=1), NBN (n=1), PRSS1 (n=1), and PTEN (n=1). In the entire cohort, the mean 21-gene RS was 20.4 in carriers and 18.0 in non-carriers (p=0.11). We performed individual analyses on specific genes identified in ≥ 5 patients (table 1). Compared to the mean RS in non-carriers (18.0), higher mean RS were observed in patients harboring BRCA1 (38.8, p=0.002), PALB2 (26.6, p=0.0724), and BRCA2 (23.2, p=0.0453). The RS in CHEK2 and ATM carriers were comparable to those of non-carriers. Conclusions: We observed differences in RS score distribution based on specific mutated breast cancer predisposition genes. Further validation of the distribution and performance of the 21-gene RS in germline carriers is needed. 21-gene RS scorenMedian RSMean≤1516-25≥26n%n%n%CHEK2251616.61248728624BRCA2182123.2211.11161.1527.8ATM101716.9330550220BRCA153635.8120120360PALB253326.6120120360None1971518.09950.367343115.7 Citation Format: Karthik V Giridhar, Grace M Choong, Siddartha Yadav, Eric C Polley, Roberto A Leon-Ferre, Minetta C Liu, Matthew P Goetz, Fergus J Couch. Distribution of the 21-gene recurrence score (RS) assay (Oncotype DX) in carriers of germline mutations associated with breast cancer predisposition syndromes [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-03-07.
Abstract P6-10-06: Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy
Pohlmann, Paula R. , Melisko, Michelle , Perlmutter, Jane , Berry, Donald A. , Pohlmann, Paula , Yau, Christina , DeMichele, Angela , Isaacs, Claudine , Boughey, Judy C. , Hylton, Nola M. , Rugo, Hope S. , Symmans, W. Fraser , Esserman, Laura J.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P6-10-06-P6-10-06

10.1158/1538-7445.sabcs19-p6-10-06 Get It

Abstract Importance: It is essential to refine the populations most likely to benefit from targeted chemotherapy combinations. Background: MINDACT showed that molecularly low risk patients, as assessed by the Amsterdam 70-gene profile MammaPrint® (Agendia) (MP), did not benefit from chemotherapy. In the I-SPY2 trial, MP low risk Hormone Receptor (HR) positive/HER2 negative patients are not eligible; however, HR negative or HER2 positive patients were considered high risk and included for treatment with chemotherapy plus novel agents. The neoadjuvant setting provides an opportunity to evaluate whether molecularly low risk HER2 positive patients are good candidates for neoadjuvant chemo/anti-HER2 therapy, where pathologic complete response (pCR) and 3-year outcomes are measured. Objective: To evaluate and further characterize the fraction of and outcomes for patients molecular low-risk disease in the I-SPY2 trial. Methods: The I-SPY2 platform trial is an ongoing multicenter phase 2 multi-arm study utilizing adaptive design and evaluating efficacy and tolerability of investigational agents in combination with standard-of-care chemotherapy for patients with high-risk anatomic stage II/III breast cancer. Patients with HR+HER2- MP low-risk tumors are not eligible. All enrolled patients undergo pretreatment biopsy for genomic evaluation of early recurrence risk with MP for risk stratification and with the 80-gene BluePrint® (Agendia) test for intrinsic subtype classification. Primary endpoint of the study is pCR in breast and lymph nodes (ypT0/is, ypN0). Secondary outcomes included event-free survival (EFS) and distant-recurrence free survival (DRFS). Following standard neoadjuvant treatment with or without a concomitant investigational agent, patients are followed for long-term outcomes. EFS and DRFS at 3 and 5 years in the pCR vs non-pCR groups within histologic and molecular subtypes are determined using the Kaplan Meier method. Results: Of the 1038 enrolled patients by November 2016, 24 patients (3.2%) had molecular low-risk disease as determined by MP. Of these, 21 (87.5%) had HR+HER2+, 1 (4.2%) had HR-HER2+, and 2 (8.4%) had HR-HER2-. BluePrint expression subtyping classified 17 as luminal-type, 6 HER2 enriched-type and 1 basal type. One patient withdrew consent for follow-up. Of the 23 remaining, none achieved pCR and only one (HR+/HER2+) had an EFS event (with median follow-up of 4.3 years). Overall, EFS and DRFS data were available for 950 of the 1038 patients (as of February 2019), with median follow-up of 3.8 years. Of the 173 HR+HER2+ in this cohort, 20 (11.6%) had molecular low-risk tumors. The EFS and DRFS for the 173 HER2+HR+ pCR group is 97% and 98% (non-pCR group 89% and 94%), respectively at 3 years. Removing the molecular low-risk HER2+ patients from the denominator reveals the worse outcome for patients with non pCR: EFS 86% and DRFS 92% at 3 years. The difference is more apparent at 5 years, changing from 74% to 66% for EFS and from 81% to 75% for DRFS. Intrinsic subtypes vary and do not predict early risk. Conclusions: I-SPY2 focuses on women with high clinical risk with only 3.2% of enrolled patients having low molecular risk tumors. However, 12% of HER+ breast cancer enrolled patients had molecular low risk tumors of which 95% were also HR+. In this group, early recurrence is very low despite absence of pCR and irrespective of intrinsic subtype. Refining the population using molecular high-risk classification of patients reveals a greater difference between the pCR and non-pCR groups within the HR+HER2+ subtype in the EFS and DRFS analysis. Clinical trial designs could address the opportunity to find more targeted and less toxic treatments for the HER2+ low molecular risk patient population. Citation Format: Paula R Pohlmann, Christina Yau, Angela DeMichele, Claudine Isaacs, Judy C Boughey, Nola Hylton, Michelle E Melisko, Jane Perlmutter, Hope S Rugo, W. Fraser Symmans, I-SPY 2 TRIAL Consortium, Donald A Berry, Laura Esserman. Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-10-06.
Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women
Palmer, Julie R. , Hu, Chunling , John, Esther M. , Haiman, Christopher A. , Hart, Steven N. , Gaudet, Mia M. , Anton‐Culver, Hoda , Gao, Chi , Huang, Hongyan , Shah, Payal D. , Yadav, Siddhartha , Yang, William , Weitzel, Jeffrey N. , Goldgar, David E. , Nathanson, Katherine L. , Polley, Eric C. , Gnanaolivu, Rohan D., Lee, Kun Y. , Na, Jie , Anton-Culver, Hoda , Weitzel, Jeffrey N , John, Esther M , Yadav, Siddhartha , Hart, Steven N , Hu, Chunling , Palmer, Julie R , Nathanson, Katherine L , Pal, Tuya , Trentham‐Dietz, Amy , Bernstein, Leslie , Ambrosone, Christine B. , Bandera, Elisa V. , Bertrand, Kimberly A. , Bethea, Traci N. , Gnanaolivu, Rohan , Marchand, Loı̈c Le , Sandler, Dale P. , Domchek, Susan M. , Kraft, Peter , Yao, Song , Couch, Fergus J.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 24, 2020 | Volume: 112 | Issue: 12 | Pages: 1213-1221

10.1093/jnci/djaa040 | PMID 32427313 Get It

Abstract Background The risks of breast cancer in African American (AA) women associated with inherited mutations in breast cancer predisposition genes are not well defined. Thus, whether multigene germline hereditary cancer testing panels are applicable to this population is unknown. We assessed associations between mutations in panel-based genes and breast cancer risk in 5054 AA women with breast cancer and 4993 unaffected AA women drawn from 10 epidemiologic studies. Methods Germline DNA samples were sequenced for mutations in 23 cancer predisposition genes using a QIAseq multiplex amplicon panel. Prevalence of mutations and odds ratios (ORs) for associations with breast cancer risk were estimated with adjustment for study design, age, and family history of breast cancer. Results Pathogenic mutations were identified in 10.3% of women with estrogen receptor (ER)-negative breast cancer, 5.2% of women with ER-positive breast cancer, and 2.3% of unaffected women. Mutations in BRCA1, BRCA2, and PALB2 were associated with high risks of breast cancer (OR = 47.55, 95% confidence interval [CI] = 10.43 to &gt;100; OR = 7.25, 95% CI = 4.07 to 14.12; OR = 8.54, 95% CI = 3.67 to 24.95, respectively). RAD51D mutations were associated with high risk of ER-negative disease (OR = 7.82, 95% CI = 1.61 to 57.42). Moderate risks were observed for CHEK2, ATM, ERCC3, and FANCC mutations with ER-positive cancer, and RECQL mutations with all breast cancer. Conclusions The study identifies genes that predispose to breast cancer in the AA population, demonstrates the validity of current breast cancer testing panels for use in AA women, and provides a basis for increased referral of AA patients for cancer genetic testing.